Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2′,6′- Dimethyl- l -tyrosine

In vitro, in vivo, and NMR-based structural studies

Takashi Yamamoto, Padma Nair, Tally M. Largent-Milnes, Neil E. Jacobsen, Peg Davis, Shou Wu Ma, Henry I. Yamamura, Todd W Vanderah, Frank Porreca, Josephine Lai, Victor J Hruby

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Multivalent ligands with δ/μ opioid agonist and NK1 antagonist activities have shown promising analgesic potency without detectable sign of toxicities, including motor skill impairment and opioid-induced tolerance. To improve their biological activities and metabolic stability, structural optimization was performed on our peptide-derived lead compounds by introducing 2′,6′-dimethyl-l-tyrosine (Dmt) instead of Tyr at the first position. The compound 7 (Dmt-d-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3′, 5′-(CF3)2-Bzl]) showed improved multivalent bioactivities compared to those of the lead compounds, had more than 6 h half-life in rat plasma, and had significant antinociceptive efficacy in vivo. The NMR structural analysis suggested that Dmt1 incorporation in compound 7 induces the structured conformation in the opioid pharmacophore (N-terminus) and simultaneously shifts the orientation of the NK1 pharmacophore (C-terminus), consistent with its affinities and activities at both opioid and NK1 receptors. These results indicate that compound 7 is a valuable research tool to seek a novel analgesic drug.

Original languageEnglish (US)
Pages (from-to)2029-2038
Number of pages10
JournalJournal of Medicinal Chemistry
Volume54
Issue number7
DOIs
StatePublished - Apr 14 2011

Fingerprint

Opioid Peptides
Opioid Analgesics
Tyrosine
Analgesics
Motor Skills
Opioid Receptors
Half-Life
Ligands
Peptides
Research
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2′,6′- Dimethyl- l -tyrosine : In vitro, in vivo, and NMR-based structural studies. / Yamamoto, Takashi; Nair, Padma; Largent-Milnes, Tally M.; Jacobsen, Neil E.; Davis, Peg; Ma, Shou Wu; Yamamura, Henry I.; Vanderah, Todd W; Porreca, Frank; Lai, Josephine; Hruby, Victor J.

In: Journal of Medicinal Chemistry, Vol. 54, No. 7, 14.04.2011, p. 2029-2038.

Research output: Contribution to journalArticle

@article{66b291ab49fa434da22701c3eee4b519,
title = "Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2′,6′- Dimethyl- l -tyrosine: In vitro, in vivo, and NMR-based structural studies",
abstract = "Multivalent ligands with δ/μ opioid agonist and NK1 antagonist activities have shown promising analgesic potency without detectable sign of toxicities, including motor skill impairment and opioid-induced tolerance. To improve their biological activities and metabolic stability, structural optimization was performed on our peptide-derived lead compounds by introducing 2′,6′-dimethyl-l-tyrosine (Dmt) instead of Tyr at the first position. The compound 7 (Dmt-d-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3′, 5′-(CF3)2-Bzl]) showed improved multivalent bioactivities compared to those of the lead compounds, had more than 6 h half-life in rat plasma, and had significant antinociceptive efficacy in vivo. The NMR structural analysis suggested that Dmt1 incorporation in compound 7 induces the structured conformation in the opioid pharmacophore (N-terminus) and simultaneously shifts the orientation of the NK1 pharmacophore (C-terminus), consistent with its affinities and activities at both opioid and NK1 receptors. These results indicate that compound 7 is a valuable research tool to seek a novel analgesic drug.",
author = "Takashi Yamamoto and Padma Nair and Largent-Milnes, {Tally M.} and Jacobsen, {Neil E.} and Peg Davis and Ma, {Shou Wu} and Yamamura, {Henry I.} and Vanderah, {Todd W} and Frank Porreca and Josephine Lai and Hruby, {Victor J}",
year = "2011",
month = "4",
day = "14",
doi = "10.1021/jm101023r",
language = "English (US)",
volume = "54",
pages = "2029--2038",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2′,6′- Dimethyl- l -tyrosine

T2 - In vitro, in vivo, and NMR-based structural studies

AU - Yamamoto, Takashi

AU - Nair, Padma

AU - Largent-Milnes, Tally M.

AU - Jacobsen, Neil E.

AU - Davis, Peg

AU - Ma, Shou Wu

AU - Yamamura, Henry I.

AU - Vanderah, Todd W

AU - Porreca, Frank

AU - Lai, Josephine

AU - Hruby, Victor J

PY - 2011/4/14

Y1 - 2011/4/14

N2 - Multivalent ligands with δ/μ opioid agonist and NK1 antagonist activities have shown promising analgesic potency without detectable sign of toxicities, including motor skill impairment and opioid-induced tolerance. To improve their biological activities and metabolic stability, structural optimization was performed on our peptide-derived lead compounds by introducing 2′,6′-dimethyl-l-tyrosine (Dmt) instead of Tyr at the first position. The compound 7 (Dmt-d-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3′, 5′-(CF3)2-Bzl]) showed improved multivalent bioactivities compared to those of the lead compounds, had more than 6 h half-life in rat plasma, and had significant antinociceptive efficacy in vivo. The NMR structural analysis suggested that Dmt1 incorporation in compound 7 induces the structured conformation in the opioid pharmacophore (N-terminus) and simultaneously shifts the orientation of the NK1 pharmacophore (C-terminus), consistent with its affinities and activities at both opioid and NK1 receptors. These results indicate that compound 7 is a valuable research tool to seek a novel analgesic drug.

AB - Multivalent ligands with δ/μ opioid agonist and NK1 antagonist activities have shown promising analgesic potency without detectable sign of toxicities, including motor skill impairment and opioid-induced tolerance. To improve their biological activities and metabolic stability, structural optimization was performed on our peptide-derived lead compounds by introducing 2′,6′-dimethyl-l-tyrosine (Dmt) instead of Tyr at the first position. The compound 7 (Dmt-d-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3′, 5′-(CF3)2-Bzl]) showed improved multivalent bioactivities compared to those of the lead compounds, had more than 6 h half-life in rat plasma, and had significant antinociceptive efficacy in vivo. The NMR structural analysis suggested that Dmt1 incorporation in compound 7 induces the structured conformation in the opioid pharmacophore (N-terminus) and simultaneously shifts the orientation of the NK1 pharmacophore (C-terminus), consistent with its affinities and activities at both opioid and NK1 receptors. These results indicate that compound 7 is a valuable research tool to seek a novel analgesic drug.

UR - http://www.scopus.com/inward/record.url?scp=79953800007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953800007&partnerID=8YFLogxK

U2 - 10.1021/jm101023r

DO - 10.1021/jm101023r

M3 - Article

VL - 54

SP - 2029

EP - 2038

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -